Ptc Therapeutics (PTCT) EBT (2012 - 2026)

Ptc Therapeutics' EBT history runs 15 years deep, the most recent figure standing at -$2.5 million for Q1 2026.

• On a quarterly basis, EBT fell 100.26% year-over-year to -$2.5 million in Q1 2026; TTM through Mar 2026 was -$235.7 million, a 118.85% decrease from a year earlier, with the FY2025 full-year figure at $696.6 million, up 195.57% from the prior year.
• EBT advanced to -$2.5 million in Q1 2026 per PTCT's latest filing, from -$139.1 million in the prior quarter.
• Across five years, EBT topped out at $929.8 million in Q1 2025 and bottomed at -$245.7 million in Q4 2023.
• The 5-year median for EBT is -$121.9 million (2022), against an average of -$26.2 million.
• Biggest YoY gain for EBT was 1197.84% in 2025; the steepest drop was 127.59% in 2025.
• Year by year, EBT stood at -$193.3 million in 2022, then slipped by 27.08% to -$245.7 million in 2023, then jumped by 305.18% to $504.1 million in 2024, then tumbled by 127.59% to -$139.1 million in 2025, then soared by 98.23% to -$2.5 million in 2026.
• Per Business Quant, the three latest PTCT EBT figures stand at -$2.5 million (Q1 2026), -$139.1 million (Q4 2025), and -$23.1 million (Q3 2025).